Ke-Shu Zhou (Keshu Zhou)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 15

Top Topics

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Top Venues

American journal of hematology

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of chemical information and modeling

This page only lists publications with an associated author ORCID identifier.

Publications

Jie Jin, Hong Cen, Ke-Shu Zhou, Xiaohong Xu, Fei Li, Tao Wu, Haiyan Yang, Zhen Wang, Zhi-Ming Li, Wenyang Huang, Hanying Bao, Zusheng Xu, Lugui Qiu
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Hao Guo, Zhe-Yuan Shen, Yong-Yi Yuan, Rou-Fen Chen, Jing-Yi Yang, Xing-Chen Liu, Qing Zhang, Qian-Ying Pan, Jian-Jun Ding, Xin-Jun He, Qing-Nan Zhang, Xiao-Wu Dong, Ke-Shu Zhou
Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment via Deep Learning and Molecular Docking. Journal of chemical information and modeling 64 (12) (2024)
Hao Guo, Zhe-Yuan Shen, Yong-Yi Yuan, Rou-Fen Chen, Jing-Yi Yang, Xing-Chen Liu, Qing Zhang, Qian-Ying Pan, Jian-Jun Ding, Xin-Jun He, Qing-Nan Zhang, Xiao-Wu Dong, Ke-Shu Zhou
Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment via Deep Learning and Molecular Docking. Journal of chemical information and modeling (2024)
Wei Xu, Ke-Shu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Han Yan, Wei Zhang, Kaiyang Ding, Jian-Feng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jian-da Hu, Chun-Yan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. American journal of hematology (2023)
Emmanuel Bachy, Kerry Joane Savage, Huiqiang Huang, Yok-Lam L Kwong, Giuseppe Gritti, Qingyuan Zhang, Anna Marina Liberati, Junning Cao, Hai-Yan Yang, Siguo Hao, Jianda Hu, Ke-Shu Zhou, Mario Petrini, Filomena Russo, Huilai Zhang, Wei Sang, Jie Ji, Andrés José Maria Ferreri, Gandhi Laurent Damaj, Wei Zhang, Hui Liu, Xiaoyan Ke, Chiara Ghiggi, Sha Huang, Xiaotong Li, Hui Yao, Jason C Paik, William Novotny, Wenxiao Zhou, Hongjie Zhu, Pier Luigi Luigi Zinzani
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open label phase 2 study. Blood advances (2023)
Yuqin Song, Ke-Shu Zhou, Dehui Zou, Dengju Li, Jian-da Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Dao-Bin Zhou, Constantine S Tam, David Simpson, Michael L Wang, Tycel J Phillips, Stephen Samuel Opat, Cheng Fang, Shaohui Sun, Jun Zhu
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis. Cancer medicine (2023)
Wei Xu, Ke-Shu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Han Yan, Wei Zhang, Kaiyang Ding, Jian-Feng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jian-da Hu, Chun-Yan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. American journal of hematology 98 (4) (2023)
Wei Xu, Ke-Shu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Han Yan, Wei Zhang, Kaiyang Ding, Jian-Feng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jian-da Hu, Chun-Yan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. American journal of hematology 98 (4) (2023)
Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhi-Ming Li, Yuqin Song, Li Zhang, Xiaojian Zhu, Huijing Wu, Wei Zhang, Junmin Li, Ke-Shu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zhenjiang Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Li-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, Ming-Zhi Zhang, Zhi-Ming Li, Chun-Yan Ji, Wei Xu, Ting Liu, Bing Xu, Xin Wang, Su-Jun Gao, Hui-Lai Zhang, Han Yan, Yan Li, Ying Cheng, Hai-Yan Yang, Jun-Ning Cao, Zunmin Zhu, Jian-Da Hu, Wei Zhang, Hong-Mei Jing, Kai-Yang Ding, Xiang-Yang Zhang, Renbin Zhao, Bin Zhang, Ya-Min Tian, Yong-Ping Song, Yu-Qin Song, Jun Zhu
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study. Blood advances (2023)
Lijuan Deng, Zhi-Ming Li, Huilai Zhang, Haiwen Huang, Jian-da Hu, Lihong Liu, Ting Liu, Jie Jin, Zunmin Zhu, Wenyu Li, Zhenqian Huang, Wenrong Huang, Ke-Shu Zhou, Haiyan Yang, Mingzhi Zhang, Kaiyang Ding, Hui Zhou, Han Yan, Yuerong Shuang, Junning Cao, Sujun Gao, Dengju Li, Zimin Sun, Qingyuan Zhang, Shuhua Yi, Chun-Yan Ji, Liansheng Zhang, Cheng Hou, Yue Du, Weige Wang, Renbin Zhao, Yuqin Song, Jun Zhu
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. American journal of hematology (2023)
Stephen Samuel Opat, Alessandra Tedeschi, Bei Hu, Kim M Linton, Pamela McKay, Sophie Leitch, Morton Coleman, Pier Luigi Luigi Zinzani, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Peter J Browett, Xiaoyan Ke, Catherine Thieblemont, Kirit M Ardeshna, Fontanet Bijou, Patricia A Walker, Eliza A Hawkes, Shir Jing Ho, Ke-Shu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood advances (2023)
Wei Xu, Ke-Shu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Han Yan, Wei Zhang, Kaiyang Ding, Jian-Feng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jian-da Hu, Chun-Yan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. American journal of hematology 98 (4) (2023)
Yuqin Song, Ke-Shu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Jane Huang, William Novotny, Pil Kim, Yiling Yu, Binghao Wu, Jun Zhu
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood 139 (21) (2022)
Haoran Wang, Wentao Zhang, Jingyi Yang, Ke-Shu Zhou
The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. Hematological oncology 39 (5) (2021)